In recent years it has been progressed in treatment of patients with Hodgkin lymphoma (HL).
Nowadays in younger patients, 5-year overall survival achieves 70–80%. Good effects of treatment
do not apply to patients over 60, who comprise 15–30% of the total HL population. Elderly patients
with HL carry a worse prognosis because of a higher incidence of advanced stages, comorbidities,
or intolerance of treatment. The literature is sparse and no prospective randomized studies exist.
This article summarizes treatment possibilities in this population of patients.
Hodgkin lymphoma, elderly patients, treatment